JP2016520192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520192A5 JP2016520192A5 JP2016514016A JP2016514016A JP2016520192A5 JP 2016520192 A5 JP2016520192 A5 JP 2016520192A5 JP 2016514016 A JP2016514016 A JP 2016514016A JP 2016514016 A JP2016514016 A JP 2016514016A JP 2016520192 A5 JP2016520192 A5 JP 2016520192A5
- Authority
- JP
- Japan
- Prior art keywords
- biomarkers
- subject
- renal function
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims 25
- 230000003907 kidney function Effects 0.000 claims 25
- 238000000034 method Methods 0.000 claims 24
- 230000035945 sensitivity Effects 0.000 claims 10
- 239000000523 sample Substances 0.000 claims 8
- 239000012472 biological sample Substances 0.000 claims 6
- -1 Eritoroneto Chemical compound 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- WUUGFSXJNOTRMR-IOSLPCCCSA-N 5'-S-methyl-5'-thioadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 WUUGFSXJNOTRMR-IOSLPCCCSA-N 0.000 claims 2
- JLQSXXWTCJPCBC-UHFFFAOYSA-N N-methyl-6-pyridone-3-carboxamide Chemical compound CN1C=C(C(N)=O)C=CC1=O JLQSXXWTCJPCBC-UHFFFAOYSA-N 0.000 claims 2
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- AFPVVTILDKMYJF-SOVPELCUSA-N (2R,3R,4S,5S)-2-(6-aminopurin-9-yl)-5-[hydroxy(sulfonyl)methyl]oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](C(O)=S(=O)=O)[C@@H](O)[C@H]1O AFPVVTILDKMYJF-SOVPELCUSA-N 0.000 claims 1
- CPXSBHKDEPPWIX-MKWJWUHGSA-N (2S)-2-amino-3-[2-[(3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-1H-indol-3-yl]propanoic acid Chemical compound C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)C1=C(C[C@H](N)C(=O)O)C2=CC=CC=C2N1 CPXSBHKDEPPWIX-MKWJWUHGSA-N 0.000 claims 1
- NPWMTBZSRRLQNJ-VKHMYHEASA-N (3s)-3-aminopiperidine-2,6-dione Chemical compound N[C@H]1CCC(=O)NC1=O NPWMTBZSRRLQNJ-VKHMYHEASA-N 0.000 claims 1
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- LUTLAXLNPLZCOF-UHFFFAOYSA-N 1-Methylhistidine Natural products OC(=O)C(N)(C)CC1=NC=CN1 LUTLAXLNPLZCOF-UHFFFAOYSA-N 0.000 claims 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims 1
- QFDRTQONISXGJA-UHFFFAOYSA-N 1-methyluric acid Chemical compound O=C1N(C)C(=O)NC2=C1NC(=O)N2 QFDRTQONISXGJA-UHFFFAOYSA-N 0.000 claims 1
- JTEYKUFKXGDTEU-UHFFFAOYSA-N 2,3-dihydroxy-3-methylbutanoic acid Chemical compound CC(C)(O)C(O)C(O)=O JTEYKUFKXGDTEU-UHFFFAOYSA-N 0.000 claims 1
- XGILAAMKEQUXLS-UHFFFAOYSA-N 3-(indol-3-yl)lactic acid Chemical compound C1=CC=C2C(CC(O)C(O)=O)=CNC2=C1 XGILAAMKEQUXLS-UHFFFAOYSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 239000004386 Erythritol Substances 0.000 claims 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 claims 1
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 claims 1
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 claims 1
- FKTXRTPBUWLETL-QMMMGPOBSA-N N-acetyl-3-methyl-L-histidine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CN=CN1C FKTXRTPBUWLETL-QMMMGPOBSA-N 0.000 claims 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 1
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims 1
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 claims 1
- 108700016464 N-acetylcarnosine Proteins 0.000 claims 1
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- HFCPFJNSBPQJDP-UHFFFAOYSA-N O-3-methylglutarylcarnitine Chemical compound [O-]C(=O)CC(C)CC(=O)OC(CC(O)=O)C[N+](C)(C)C HFCPFJNSBPQJDP-UHFFFAOYSA-N 0.000 claims 1
- NXJAXUYOQLTISD-SECBINFHSA-N O-glutaroyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCCC(O)=O NXJAXUYOQLTISD-SECBINFHSA-N 0.000 claims 1
- LRCNOZRCYBNMEP-SECBINFHSA-N O-isobutyryl-L-carnitine Chemical compound CC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C LRCNOZRCYBNMEP-SECBINFHSA-N 0.000 claims 1
- ONPXCLZMBSJLSP-CSMHCCOUSA-N Pro-Hyp Chemical compound C1[C@H](O)C[C@@H](C(O)=O)N1C(=O)[C@H]1NCCC1 ONPXCLZMBSJLSP-CSMHCCOUSA-N 0.000 claims 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- ONJSZLXSECQROL-UHFFFAOYSA-N alpha-hydroxyhippuric acid Natural products OC(=O)CNC(=O)C1=CC=CC=C1O ONJSZLXSECQROL-UHFFFAOYSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 1
- XUYANFPPYJSBPU-QMMMGPOBSA-N bisorcic Chemical compound CC(=O)NCCC[C@@H](C(O)=O)NC(C)=O XUYANFPPYJSBPU-QMMMGPOBSA-N 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 229940109239 creatinine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 1
- 229940009714 erythritol Drugs 0.000 claims 1
- 235000019414 erythritol Nutrition 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- AQTYXAPIHMXAAV-UHFFFAOYSA-M guaiacol sulfate(1-) Chemical compound COC1=CC=CC=C1OS([O-])(=O)=O AQTYXAPIHMXAAV-UHFFFAOYSA-M 0.000 claims 1
- DHRNMNHPSWBJEN-UHFFFAOYSA-N hydroxyisovaleroyl carnitine Chemical compound CC(C)CC(=O)OC(O)(CC([O-])=O)C[N+](C)(C)C DHRNMNHPSWBJEN-UHFFFAOYSA-N 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 238000013178 mathematical model Methods 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- KTHDTJVBEPMMGL-GSVOUGTGSA-N n-acetylalanine Chemical compound OC(=O)[C@@H](C)NC(C)=O KTHDTJVBEPMMGL-GSVOUGTGSA-N 0.000 claims 1
- 229940099459 n-acetylmethionine Drugs 0.000 claims 1
- 230000003589 nefrotoxic effect Effects 0.000 claims 1
- 231100000381 nephrotoxic Toxicity 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 claims 1
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- HAEVNYBCYZZDFL-MRVPVSSYSA-N succinyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCC(O)=O HAEVNYBCYZZDFL-MRVPVSSYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822965P | 2013-05-14 | 2013-05-14 | |
| US61/822,965 | 2013-05-14 | ||
| PCT/US2014/037762 WO2014186311A1 (en) | 2013-05-14 | 2014-05-13 | Biomarkers related to kidney function and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016520192A JP2016520192A (ja) | 2016-07-11 |
| JP2016520192A5 true JP2016520192A5 (enExample) | 2017-06-22 |
| JP6595984B2 JP6595984B2 (ja) | 2019-10-23 |
Family
ID=51898805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016514016A Active JP6595984B2 (ja) | 2013-05-14 | 2014-05-13 | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10539575B2 (enExample) |
| EP (3) | EP3410115A1 (enExample) |
| JP (1) | JP6595984B2 (enExample) |
| CN (2) | CN110196335A (enExample) |
| AU (1) | AU2014265669B2 (enExample) |
| BR (1) | BR112015028253A2 (enExample) |
| CA (2) | CA3184836A1 (enExample) |
| ES (2) | ES2871823T3 (enExample) |
| MX (2) | MX365061B (enExample) |
| WO (1) | WO2014186311A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3410115A1 (en) * | 2013-05-14 | 2018-12-05 | Metabolon, Inc. | Tryptophan as a biomarkers for kidney function and methods using the same |
| WO2015057968A2 (en) | 2013-10-17 | 2015-04-23 | The General Hospital Corporation | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
| HUE047951T2 (hu) * | 2015-01-09 | 2020-05-28 | Global Genomics Group Llc | Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására |
| US20180003721A1 (en) * | 2015-01-15 | 2018-01-04 | Joslin Diabetes Center | Metabolite Biomarkers Predictive Of Renal Disease In Diabetic Patients |
| WO2017059132A1 (en) * | 2015-09-29 | 2017-04-06 | The General Hospital Corporation | Methods of treating and diagnosing disease using biomarkers for bcg therapy |
| US20170234874A1 (en) * | 2015-10-07 | 2017-08-17 | Clearbridge Biophotonics Pte Ltd. | Integrated visual morphology and cell protein expression using resonance-light scattering |
| US12057228B1 (en) * | 2015-12-30 | 2024-08-06 | Cerner Innovation, Inc. | Predicting newly incident chronic kidney disease |
| US10865183B2 (en) | 2016-07-28 | 2020-12-15 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| EP3552022B1 (en) * | 2016-11-25 | 2021-06-09 | Implexion AB | Metabolic disorders |
| ES3004083T3 (en) * | 2016-12-19 | 2025-03-11 | Metabolon Inc | Mass spectrometry assay method for detection and quantitation of kidney function metabolites |
| CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
| CN107132266A (zh) * | 2017-06-21 | 2017-09-05 | 佛山科学技术学院 | 一种基于随机森林的水质分类方法及系统 |
| AU2018313853A1 (en) | 2017-08-08 | 2020-01-02 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| CN107326093B (zh) * | 2017-09-04 | 2020-01-21 | 东南大学 | 基于Taqman探针的慢性肾脏病相关基因检测荧光定量PCR一步法试剂盒及其应用 |
| US11680042B2 (en) * | 2017-09-28 | 2023-06-20 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
| CA3089817A1 (en) * | 2018-01-19 | 2019-07-25 | Mars, Incorporated | Biomarkers and classification algorithms for chronic kidney disease in cats |
| JP7633147B2 (ja) * | 2018-07-14 | 2025-02-19 | マース インコーポレーテッド | 慢性腎臓病のためのバイオマーカー及びテストモデル |
| CN113454462A (zh) * | 2019-02-20 | 2021-09-28 | 株式会社合伙企业 | 固相反应芯片和使用该固相反应芯片的测定方法 |
| CN112305089B (zh) * | 2019-07-26 | 2022-04-29 | 长沙都正生物科技股份有限公司 | 一种慢性肾病诊断生物标记物及其应用 |
| CN114269722B (zh) * | 2019-07-26 | 2024-11-22 | 贝尔维奇生物医学研究所(伊迪贝尔) | 麦角硫因、s-甲基-麦角硫因及其用途 |
| CN111487338B (zh) * | 2020-04-16 | 2022-06-10 | 中南大学湘雅二医院 | 一种与肾功能相关的无创生物标记物及其应用 |
| CN114026427B (zh) * | 2020-05-19 | 2023-11-17 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| KR102697110B1 (ko) | 2020-12-07 | 2024-08-22 | 킴벌리-클라크 월드와이드, 인크. | 대사산물을 검출하기 위한 방법 및 소비자 제품 |
| AU2022426744A1 (en) * | 2021-12-27 | 2024-05-23 | Société des Produits Nestlé S.A. | Compositions and methods for diagnosing and treating chronic kidney disease |
| CN114910587B (zh) * | 2022-05-12 | 2024-03-19 | 军科正源(上海)生物医药科技有限公司 | 一种尿液检测用高效液相-串联质谱分析方法 |
| WO2026120352A1 (en) * | 2024-12-03 | 2026-06-11 | Societe Des Produits Nestle Sa | Estimating glomerular filtration rates in felines |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196787A (ja) | 1989-01-25 | 1990-08-03 | Otsuka Pharmaceut Co Ltd | シュードウリジン誘導体 |
| JPH0661278B2 (ja) | 1990-09-18 | 1994-08-17 | 旭化成工業株式会社 | ミオイノシトールの高感度定量法および定量用組成物 |
| US5712084A (en) * | 1995-09-08 | 1998-01-27 | Research Corporation Technologies, Inc. | Donor kidney viability test for improved preservation |
| CN101377492B (zh) | 2007-08-29 | 2014-04-23 | 北京九强生物技术股份有限公司 | 胱抑素c测定试剂盒 |
| CA2735590A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9421330B2 (en) * | 2008-11-03 | 2016-08-23 | Bayer Healthcare Llc | Mitigation of contrast-induced nephropathy |
| EP2364370B1 (en) * | 2008-11-22 | 2014-09-03 | Astute Medical, Inc. | Methods for prognosis of acute renal failure |
| US20100273207A1 (en) | 2009-04-24 | 2010-10-28 | Raymond Langley | Methods for Diagnosis of Sepsis and Risk of Death |
| WO2010126146A1 (ja) | 2009-04-30 | 2010-11-04 | Tanaka Noriaki | 腎疾患重篤度を判定する方法又は装置若しくはその作動方法 |
| EP2440214A4 (en) * | 2009-06-08 | 2013-07-31 | Quark Pharmaceuticals Inc | METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES |
| US8709816B2 (en) | 2009-09-04 | 2014-04-29 | Tohoku University | Human renal disease marker substance |
| MX342967B (es) | 2009-12-20 | 2016-10-19 | Astute Medical Inc | Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal. |
| WO2011146683A1 (en) | 2010-05-19 | 2011-11-24 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
| JP5899213B2 (ja) | 2010-08-06 | 2016-04-06 | マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ | 腎機能不全のバイオマーカーとしてのパールカン |
| JP5916058B2 (ja) | 2011-08-26 | 2016-05-11 | 国立大学法人東北大学 | 細胞ストレス状態のバイオマーカー |
| CA2845117A1 (en) | 2011-09-14 | 2013-03-21 | Basf Se | Means and methods for assessing kidney toxicity |
| WO2013048344A1 (en) * | 2011-09-29 | 2013-04-04 | National University Of Singapore | Urinary metabolomic markers for renal insufficiency |
| EP3410115A1 (en) * | 2013-05-14 | 2018-12-05 | Metabolon, Inc. | Tryptophan as a biomarkers for kidney function and methods using the same |
| US10865183B2 (en) * | 2016-07-28 | 2020-12-15 | Metabolon, Inc. | Compounds, reagents, and uses thereof |
-
2014
- 2014-05-13 EP EP18183240.3A patent/EP3410115A1/en not_active Withdrawn
- 2014-05-13 WO PCT/US2014/037762 patent/WO2014186311A1/en not_active Ceased
- 2014-05-13 BR BR112015028253A patent/BR112015028253A2/pt not_active Application Discontinuation
- 2014-05-13 US US14/889,930 patent/US10539575B2/en active Active
- 2014-05-13 CA CA3184836A patent/CA3184836A1/en active Pending
- 2014-05-13 CN CN201910484069.9A patent/CN110196335A/zh active Pending
- 2014-05-13 AU AU2014265669A patent/AU2014265669B2/en active Active
- 2014-05-13 MX MX2015015561A patent/MX365061B/es active IP Right Grant
- 2014-05-13 JP JP2016514016A patent/JP6595984B2/ja active Active
- 2014-05-13 CN CN201480027332.7A patent/CN105209909B/zh active Active
- 2014-05-13 ES ES19176215T patent/ES2871823T3/es active Active
- 2014-05-13 ES ES14797070T patent/ES2702123T3/es active Active
- 2014-05-13 CA CA2911204A patent/CA2911204C/en active Active
- 2014-05-13 EP EP14797070.1A patent/EP2997366B1/en active Active
- 2014-05-13 EP EP19176215.2A patent/EP3546940B1/en active Active
- 2014-05-13 MX MX2019005748A patent/MX391220B/es unknown
-
2019
- 2019-12-02 US US16/700,098 patent/US20200103417A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6595984B2 (ja) | 腎機能に関連付けられるバイオマーカーおよびそれを使用する方法 | |
| Lin et al. | False-positive rate of AKI using consensus creatinine–based criteria | |
| JP2018502286A5 (enExample) | ||
| Nolan et al. | Prevalence of chronic kidney disease and progression of disease over time among patients enrolled in the Houston West Nile virus cohort | |
| Hanna et al. | Early urinary biomarkers of acute kidney injury in preterm infants | |
| WO2019209874A2 (en) | Markers of immune wellness and methods of use thereof | |
| US20190156919A1 (en) | Determining relationships between risks for biological conditions and dynamic analytes | |
| JP2016509222A5 (enExample) | ||
| US20250087362A1 (en) | System and method of generating a model to detect, or predict the risk of, an outcome | |
| Franciosi et al. | Susceptibility to COPD: differential proteomic profiling after acute smoking | |
| JP2015514227A5 (enExample) | ||
| Shah et al. | Calibration-free concentration analysis of protein biomarkers in human serum using surface plasmon resonance | |
| RU2020134037A (ru) | Способы скрининга субъекта на риск развития хронической болезни почек и компьютерно-реализуемый способ | |
| JP6762529B2 (ja) | 腎臓病の病態バイオマーカー | |
| JP2016526167A5 (enExample) | ||
| Basu et al. | Improving acute kidney injury diagnostics using predictive analytics | |
| KR101806136B1 (ko) | 대사체 분석을 이용한 베체트병 관절염의 진단방법 | |
| Gowrishankar et al. | Value of serum cystatin C in estimating renal function in children with non‐renal solid organ transplantation | |
| Almalky et al. | Detection of early renal injury in children with solid tumors undergoing chemotherapy by urinary neutrophil gelatinase-associated lipocalin | |
| Watanabe et al. | Albumin as a Biomarker | |
| Islam et al. | Comparative analyses of adsorbed circulating proteins in the PMMA and PES hemodiafilters in patients on predilution online hemodiafiltration | |
| FI3543702T3 (fi) | Menetelmiä koehenkilön kroonisen munuaissairauden riskin seulomiseksi ja tietokoneella toteutettu menetelmä | |
| US20250210192A1 (en) | Methods for disease detection | |
| CN114113560A (zh) | 用于估算肾小球滤过率(gfr)的血代谢标记物及其应用 | |
| Imamoglu | Ismail Kocyigit, Eray Eroglu, Ozcan Orscelik, Aydin Unal, Ozkan Gungor, Fahir Ozturk, Cigdem Karakukcu |